Without insurance in 2026, Wegovy has a list price above one thousand dollars for a one-month supply, but almost no cash payer pays that. The manufacturer self-pay program brings the monthly figure to a few hundred dollars for people willing to accept its refill conditions, and compounded routes can land lower still while carrying a real regulatory trade-off. The honest answer is a range, not a single number, because it depends on which route you use.
Why is there no single Wegovy price?
List price is the sticker, and it exists mostly as a starting point for negotiations you never see. What a cash buyer pays comes from a specific route: the maker’s direct self-pay program, a pharmacy discount card, or a compounded product prescribed through a telehealth practice. Each route sets its own number, and the numbers do not overlap much. A person quoting the list price and a person on the self-pay program are describing two different realities.
This matters because the wrong reference point leads to bad decisions. Someone who assumes Wegovy costs the full list price may abandon treatment or jump to an unvetted source when a legitimate cheaper route was available the whole time. So the first job is to sort the routes, then compare prices only within a route.
What are the routes to a cash price?
| Route | What sets the number | Main limitation |
|---|---|---|
| List price at retail | Manufacturer wholesale plus pharmacy markup | Almost nobody actually pays it |
| Manufacturer self-pay | Fixed cash price set by the maker | Refill-timing and enrollment conditions |
| Pharmacy discount card | Card network’s negotiated rate | Varies by pharmacy and often exceeds self-pay |
| Compounded semaglutide | Pharmacy and provider pricing | Not an FDA-approved product |
How does the manufacturer self-pay program work?
Novo Nordisk sells Wegovy directly to cash-paying patients at a price well under list, and that program has become the default answer for people without coverage. It brought brand semaglutide within reach of people who would otherwise have been priced out entirely. It also carries conditions. Refills often need to be filled within a set window, pricing can shift depending on whether you stay enrolled, and the advertised figure sometimes assumes the standard dosing progression described in the Wegovy label. The Wegovy prescribing information at DailyMed lays out that dose escalation, which is why the early months and the maintenance months can price differently.
The practical lesson: look at the sustainable monthly figure, not the introductory one. A program that is cheap for month one and jumps later is not a bargain if you plan to stay on treatment for a year or more.
Why do savings cards not help cash payers much?
Commercial savings cards are frequently misread. The largest advertised reduction usually assumes you already hold commercial insurance that pays part of the bill, with the card trimming the leftover copay. A person with no insurance at all rarely qualifies for that headline number, and people on Medicare or Medicaid are generally excluded from commercial copay assistance entirely. For a true cash payer, the self-pay program and compounded options are the real field, not the copay card.
Pharmacy discount cards are a separate thing and can help at the counter, but their negotiated rate often sits above the manufacturer self-pay price. It is worth checking both rather than assuming the card wins.
Where do compounded options fit?
Compounded semaglutide is prepared by a compounding pharmacy rather than manufactured under an approved application. It is not an FDA-approved product, and it has not been through the process that generated Wegovy’s trial evidence. The FDA has published warnings and guidance on medications containing semaglutide outside the approved products, and that distinction is a genuine one rather than a formality.
What compounded routes often offer is a predictable flat monthly cash price with no insurance involved. Supervised telehealth practices such as FormBlends publish that kind of pricing and prescribe through a licensed clinician; their explainer on how much Wegovy costs without insurance is one of several places that lay out the self-pay math for comparison. Ro, Hims and Hers, Henry Meds, and NovoCare cover the same decision from different angles. The trade is straightforward: compounded products swap regulatory assurance for cost predictability, and whether that swap is reasonable is a conversation for a prescriber who knows the case, not a website.
Does the price justify the drug at all?
For the right patient, the clinical case for semaglutide is strong, and that is worth weighing against the monthly cost. In the STEP 3 trial, semaglutide paired with intensive behavioral therapy produced mean weight loss around 16 percent, reported in the 2021 STEP 3 results. The STEP 8 trial, published in 2022, found semaglutide outperformed daily liraglutide on body weight. The 2025 obesity pharmacotherapy guideline update, available here, places semaglutide among the first-line options, and the newer clinical definition of obesity discussed in this 2025 paper helps clarify who benefits most.
The catch, and it is a real one, is durability. The STEP 4 randomized trial showed that continuing semaglutide maintained weight loss while switching to placebo led to regain, reported in 2021. The STEP 1 extension confirmed most lost weight returns after the drug stops. So the honest cost question is not one month but the sustained monthly figure over a year or longer, because stopping early tends to undo the result.
Key takeaways
- Wegovy’s list price sits above a thousand dollars a month, but cash payers rarely pay it.
- The manufacturer self-pay program is the usual answer for people without coverage, subject to refill conditions.
- Commercial savings cards mostly help people who already have commercial insurance.
- Compounded semaglutide can cost less but is not an FDA-approved product.
- Trial evidence shows weight tends to return after stopping, so the sustained monthly price is the number that matters.
Frequently asked questions
What is the list price of Wegovy without insurance?
The published list price sits above one thousand dollars for a month of Wegovy. Almost nobody pays that number, because the manufacturer self-pay program and pharmacy discounts land well below it for cash buyers.
Is the manufacturer self-pay program cheaper than a pharmacy discount card?
Often yes, but it comes with conditions on refill timing and enrollment. The sustainable monthly price under those conditions matters more than the first month’s figure.
Do savings cards help if I have no insurance at all?
Usually not. Commercial copay cards assume you already have commercial coverage that partly pays. Cash payers should look at the manufacturer self-pay route or compounded options instead.
Is compounded semaglutide the same as Wegovy?
No. Compounded semaglutide is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule, but it has not been through the approval process behind Wegovy’s trial evidence.
What should be checked before paying cash?
Whether any plan or discount actually applies, what the self-pay refill rules require, and whether the prescription is being managed by a licensed clinician. The cheapest option is not always the one that is sustainable month to month.
